Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹10,711 Cr
Revenue (TTM)
₹3,263 Cr
Net Profit (TTM)
₹439 Cr
ROE
20.5 %
ROCE
25.2 %
P/E Ratio
24.4
P/B Ratio
3.6
Industry P/E
--
EV/EBITDA
14.8
Div. Yield
0.4 %
Debt to Equity
0
Book Value
₹123.4
EPS
₹18.3
Face value
2
Shares outstanding
240,480,084
CFO
₹1,715.75 Cr
EBITDA
₹2,289.32 Cr
Net Profit
₹1,499.81 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Indegene
| -14.4 | -10.3 | -16.8 | -15.9 | -- | -- | -- |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
|---|---|
|
Indegene
| -14.2 |
|
BSE Small Cap
| -6.6 |
|
BSE Healthcare
| -3.3 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Indegene
|
445.7 | 10,711.0 | 3,262.7 | 439.0 | 15.3 | 16 | 24.4 | 3.6 |
| 160.3 | 2,562.6 | 2,796.8 | 118.8 | 8.1 | 2.3 | 21.6 | 0.4 | |
| 28.4 | 8.7 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 2.2 | |
| 52.6 | 192.2 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 1.9 | |
| 161.4 | 7,386.6 | 2,803.3 | 361.8 | 15.5 | 14 | 20.5 | 2.6 | |
| 21.4 | 644.4 | 1,450.4 | 47.9 | 6.6 | 10.1 | 14.4 | 1.4 | |
| 1,008.8 | 21,334.6 | 2,169.9 | 332.9 | 20.9 | 15.4 | 64.1 | 9.0 | |
| 4,217.7 | 9,735.5 | 878.4 | 240.1 | 33.8 | 73.3 | 40.5 | 25.4 | |
| 38.1 | 564.1 | 0.0 | 1.6 | -- | -0.5 | 350.6 | 21.0 | |
| 25.3 | 54.7 | 51.4 | 4.5 | 22.0 | 5.2 | 12.1 | 0.6 |
5 min read•By Samridh Rela
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions,... Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India. Read more
Incorporated
1998
Chairman
Manish Gupta
Managing Director
--
Headquarters
Bengaluru, Karnataka
Website
Looking for more details about Indegene Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Indegene Ltd is ₹445.65 (NSE) and ₹450.05 (BSE) as of 19-Mar-2026 15:54 IST. Indegene Ltd has given a return of -15.87% in the last 1 years.
The P/E ratio of Indegene Ltd is 24.40 times as on 19-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
34.05
|
5.37
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Indegene Ltd are Rs 632.90 and Rs 423.00 as of 19-Mar-2026.
Indegene Ltd has a market capitalisation of ₹ 10,711 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Indegene Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-7.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.